Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

BACKGROUND: Addition of oxaliplatin to capecitabine remains controversial for locally advanced rectal cancer (LARC). And cumulative oxaliplatin dose (COD) varied among clinical trials showing different therapeutic effects of this regimen. The objective of this study was to explore how COD affected t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hui, Tao, Ya-lan, Jiang, Wu, Chen, Chen, Liu, Shi-liang, Ye, Wei-jun, Gao, Yuan-hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268650/
https://www.ncbi.nlm.nih.gov/pubmed/32487091
http://dx.doi.org/10.1186/s12885-020-06988-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268650/
https://www.ncbi.nlm.nih.gov/pubmed/32487091
http://dx.doi.org/10.1186/s12885-020-06988-x

Ejemplares similares